ライフサイエンスコーパス: postexposure

1 posure and with distinct behavioral profiles postexposure.

2 both species succumbed between days 9 and 11 postexposure.

3 tection in multiple animal models up to 24 h postexposure.

4 ovascular function declined starting at 20 h postexposure.

5 , with additional treatments on days 4 and 8 postexposure.

6 g the infection despite drugs at early times postexposure.

7 Dyspnea manifested 2 to 4 days postexposure.

8 mg dose of doxycycline given within 72 hours postexposure.

9 , with additional treatments on days 4 and 8 postexposure.

10 d over 20 to 30 days and declined by 45 days postexposure.

11 dent increases in hair cell survival at 24 h postexposure.

12 hal respiratory tularemia when given 24-48 h postexposure.

13 OVID-19 at a mean of 3.65 (range: 0-17) days postexposure.

14 precipitous decline in infection after day 7 postexposure.

15 ilic airway inflammation that peaked at 18 h postexposure.

16 t lymphocyte decreases between days 8 and 11 postexposure.

17 CL10, CCL3, and CCL7 mRNA was sustained 18 h postexposure.

18 tic drops in their CD4(+) T cells by 2 weeks postexposure.

19 ually die via apoptosis starting 4 to 6 days postexposure.

20 prostates despite undetectable free BPA 1 hr postexposure.

21 IL-12 expression, which persisted up to 12 d postexposure.

22 tered in mice exposed to viable vs. HIC 48 h postexposure.

23 rosolized Marburg virus was evident at 1 day postexposure.

24 f disease and quantitated for virus shedding postexposure.

25 xposure, immediately postexposure, and 20 hr postexposure.

26 outcomes during, immediately after, and 2 hr postexposures.

27 By 10 days postexposure, AChE-R prophylaxis markedly limited postex

28 mouse-adapted H3N2 strains, in both pre- and postexposure administration regimens.

29 pirometry was performed immediately pre- and postexposure and bronchoalveolar lavage (BAL) was obtain

30 vaccine is determined to be highly effective postexposure and if it is feasible, vaccinating househol

31 unoprotectant should be further pursued as a postexposure and potential therapeutic for Ebola virus e

32 Postexposure and preexposure geometric mean salivary cot

33 les immediately before and after the visits (postexposure) and on the following morning and analyzed

34 the brachial artery preexposure, immediately postexposure, and 20 hr postexposure.

35 ctant protein-3), and CCL11 (eotaxin) at 0 h postexposure, and expression of CXCL10, CCL3, and CCL7 m

36 These studies clearly demonstrate that postexposure antibody treatments can protect NHPs and op

37 Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known

38 ated the generation of latent images without postexposure baking, providing a practical approach for

39 cyclobutane thymine dimer levels peaked 3 d postexposure, before returning to baseline.

40 Postexposure challenge of gammaHV68-infected I-A(b+/+) a

41 Postexposure challenge with recombinant vaccinia viruses

42 These postexposure changes endured into adulthood.

43 Beginning around day 8 to day 10 postexposure, clinical signs consistent with encephaliti

44 ammatory responses in the mouse lung at 24 h postexposure compared to the fine and ultrafine PM, and

45 ladder, and joint tissue obtained at 8 weeks postexposure did not reveal greater pathology in mice in

46 Postexposure discrimination of other stimuli was unaffec

47 ients, but a single 45 mg dose of primaquine postexposure does not completely prevent blood-stage par

48 before virus exposure, followed by a booster postexposure dose.

49 ort, significant valvular disease on initial postexposure echocardiography was common in this cohort;

50 ly attractive candidates due to their proven postexposure efficacy in nonhuman primate models of EBOV

51 e, the bivalent vaccine has slightly reduced postexposure efficacy most likely due to its restricted

52 Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with an

53 Significant postexposure efficacy of several MAbs, including a novel

54 rior to bacterial colonization (1 to 14 days postexposure), enriched fecal cultures were more sensiti

55 No postexposure etching or bonding is required; the channel

56 The postexposure fluorescence quenching as well as the sensi

57 oxidizing reagents did not demonstrate this postexposure fluorescence quenching; rather, a recovery

58 nical signs were fever developing 24 to 40 h postexposure followed by leukocytosis resulting from a h

59 amples were collected pre-exposure and daily postexposure, for up to 13 d.

60 scores compared with baseline and had higher postexposure global scores than the sunscreen group (0.7

61 ate that convalescent FFP shows promise as a postexposure HPS prophylactic.

62 The postexposure IgG treatment was completely protective, wi

63 Pre- and immediate postexposure images of the photoreceptors and RPE cells

64 Postexposure immunization can prevent disease and reduce

65 nd also demonstrate the potential value of a postexposure immunoprophylactic to treat individuals aft

66 mework for humanization and development of a postexposure immunotherapeutic.

67 immunizations or provide protection through postexposure immunotherapeutics are long-sought goals.

68 virus infections, both prophylactically and postexposure in a homologous challenge setting.

69 The results represent successful postexposure in vivo efficacy by a mAb mixture and sugge

70 xposure, AChE-R prophylaxis markedly limited postexposure increases in plasma murine AChE-R levels wh

71 Cellular responses were monitored with postexposure incubation in submerged conditions, reveali

72 of the blast OPW-produced energy waves with postexposure inflammatory events has not yet been deline

73 el, safe, and effective emergency therapy of postexposure inhalation anthrax.

74 CD4 and CD8 cell apoptosis as early as 12 h postexposure; inhibition of CD4 and CD8 cell cycle progr

75 mpared by vaccine exposure status during the postexposure interval.

76 a new model for evaluating prophylactic and postexposure interventions prior to testing in NHPs.

77 to 3 days postexposure; midinfection, 5 days postexposure; late infection, 7 to 9 days postexposure)

78 The demonstration of successful postexposure MAb 201 therapy in an animal model that dem

79 lesticks including universal precautions and postexposure management of occupational HIV, hepatitis B

80 ns at high risk for infection or who require postexposure management.

81 spores, particularly if not done immediately postexposure, may not be very effective for detecting B.

82 Pre- and postexposure measurements were compared, and Pearson cor

83 tage induction (early infection, 1 to 3 days postexposure; midinfection, 5 days postexposure; late in

84 urvival, whereas it induced mild to moderate postexposure mortality in the larval stage and at metamo

85 haryngeal lymphoid tissues at 1 and 2 months postexposure (MPE).

86 viduals along with a description of symptoms postexposure, or the proportion of measles cases that ha

87 strain CO92 and necropsied at 24-h intervals postexposure (p.e.).

88 al changes were identified as early as day 3 postexposure (p.e.).

89 08, through December 31, 2010 (3 years); the postexposure period, January 1 through December 31, 2011

90 or ciprofloxacin may be useful in the early postexposure period.

91 cer and will be superior vaccine choices for postexposure poxvirus vaccination, as they also provide

92 ) at 3 monthly iterations, and some received postexposure primaquine (CVac-primaquine/chloroquine arm

93 photoresist SU-8, and following exposure and postexposure processing, the resulting SU-8 features had

94 ing that these organisms have potential as a postexposure prophylactic.

95 here are no FDA-licensed vaccines, effective postexposure prophylactics, or therapeutics.

96 d or body fluid exposures that might warrant postexposure prophylaxis (e.g., needlestick injury to a

97 Nonoccupational postexposure prophylaxis (nPEP) is recommended after a s

98 Postexposure prophylaxis (PEP) after intravaginal exposu

99 The feasibility of providing postexposure prophylaxis (PEP) after sexual or injection

100 We determined the efficacy of postexposure prophylaxis (PEP) and treatment of ill inde

101 rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low.

102 guidelines for human immunodeficiency virus postexposure prophylaxis (PEP) are the first to combine

103 rld Health Organization (WHO) guidelines for postexposure prophylaxis (PEP) developed recommendations

104 In the mouse models, the postexposure prophylaxis (PEP) efficacy obtained with th

105 Antibiotic postexposure prophylaxis (PEP) following pertussis expos

106 velopment Group meeting, recommendations for postexposure prophylaxis (PEP) for human immunodeficienc

107 in the decision on how to treat and provide postexposure prophylaxis (PEP) for plague during pregnan

108 e individuals who present for antiretroviral postexposure prophylaxis (PEP) had a 1-time exposure to

109 Preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) has been shown to be effe

110 ed regimens for human immunodeficiency virus postexposure prophylaxis (PEP) has evolved over the last

111 However, immunoglobulin (IgG)-based rabies postexposure prophylaxis (PEP) is expensive, restricting

112 arter packs for human immunodeficiency virus postexposure prophylaxis (PEP) is practiced in many sett

113 Rabies virus (RABV) postexposure prophylaxis (PEP) requires rapid vaccine-in

114 us (RV) research is to develop a single-dose postexposure prophylaxis (PEP) that would simplify vacci

115 The efficacy of antiretrovirals as postexposure prophylaxis (PEP) to prevent viral acquisit

116 New recommendations for rabies postexposure prophylaxis (PEP) were published by the Cen

117 screening for urine/kidney exposure; and (5) postexposure prophylaxis (PEP) when indicated.

118 HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP) when necessary; however,

119 In a nonrandomized study of nonoccupational postexposure prophylaxis (PEP), a cross-sectional evalua

120 of mother-to-child transmission (PMTCT), and postexposure prophylaxis (PEP)-are all strongly recommen

121 or PrEP compares favorably with evidence for postexposure prophylaxis (PEP).

122 fied for its potential application in rabies postexposure prophylaxis (PEP).

123 ys have not been evaluated in the setting of postexposure prophylaxis (PEP).

124 y and efficacy of antiretroviral options for postexposure prophylaxis (PEP).

125 single-visit rabies vaccination for pre- and postexposure prophylaxis (PrEP and PEP) could substantia

126 detected in their serum after completion of postexposure prophylaxis (range, 0.3-40.8 IU/mL).

127 Rabies postexposure prophylaxis (RPEP) treatments and associate

128 Postexposure prophylaxis 4 days after challenge was 100%

129 1R-specific neutralizing antibodies afforded postexposure prophylaxis after systemic vaccinia virus i

130 infrastructure prevents timely reporting and postexposure prophylaxis and the ubiquity of domestic an

131 In both postexposure prophylaxis and treatment of acute infectio

132 Both postexposure prophylaxis and treatment of varicella are

133 ies is a novel finding with implications for postexposure prophylaxis and vaccines.

134 igational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the Unite

135 lescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious

136 rhoeae or C. trachomatis, and the use of HIV postexposure prophylaxis are discussed.

137 Postexposure prophylaxis can offer protection against HI

138 Our findings show that postexposure prophylaxis can successfully prevent hepati

139 A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19.

140 ic data in humans, AVI-7288 has potential as postexposure prophylaxis for MARV infection in humans.

141 , there are no national guidelines regarding postexposure prophylaxis for nonoccupational exposures.

142 The use of postexposure prophylaxis for occupational and perinatal

143 clinical trials to prove the efficacy of ART postexposure prophylaxis has not been possible.

144 Clinicians should consider initiating postexposure prophylaxis in adolescents for any oral, an

145 eded to characterize the use and efficacy of postexposure prophylaxis in an adolescent population.

146 easonable alternative to immune globulin for postexposure prophylaxis in many situations.

147 end an extra intramuscular dose be given for postexposure prophylaxis in previously unvaccinated pers

148 imely distribution of effective treatment or postexposure prophylaxis in the aftermath of the release

149 Postexposure prophylaxis is an effective intervention to

150 lock lentivirus infection, but their role in postexposure prophylaxis is poorly understood.

151 Postexposure prophylaxis is recommended for all persons

152 Postexposure prophylaxis is the primary means of treatin

153 ssion of HIV after sexual abuse is rare, HIV postexposure prophylaxis must be administered in a timel

154 canine rabies but also for late-stage rabies postexposure prophylaxis of humans.

155 Postexposure prophylaxis of inhalational anthrax require

156 ccine candidate for both the preexposure and postexposure prophylaxis of rabies.

157 designed primarily to estimate the effect of postexposure prophylaxis on preventing influenza illness

158 w trials that allow their inclusion focus on postexposure prophylaxis or outpatient treatment of mild

159 Although current postexposure prophylaxis rabies virus (RV) vaccines are

160 The current postexposure prophylaxis regimen for tick-borne relapsin

161 ansfer experiments in mice, both in pre- and postexposure prophylaxis regimens.

162 rified chick embryo cell vaccine, given on a postexposure prophylaxis schedule.

163 f VNAs to protect against RABV infections in postexposure prophylaxis settings, these findings may he

164 When indicated, postexposure prophylaxis should be started as soon as po

165 Postexposure prophylaxis should follow region-appropriat

166 immunodeficiency virus type 1 (HIV) pre- and postexposure prophylaxis show promise.

167 Here, we evaluated the feasibility of two postexposure prophylaxis strategies in the ANDV/hamster

168 y meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection

169 immunodeficiency virus (HIV) nonoccupational postexposure prophylaxis using an algorithm to assess th

170 Rabies postexposure prophylaxis was considered inappropriately

171 V); 4 neonates were then given intramuscular postexposure prophylaxis with 3 anti-HIV human neutraliz

172 Despite postexposure prophylaxis with antibiotics, inhalation of

173 t product B, product recalls took place, and postexposure prophylaxis with both hepatitis A virus vac

174 Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.

175 ne globulin is a crucial component of rabies postexposure prophylaxis, and here we also show that it

176 l contexts, including maternal transmission, postexposure prophylaxis, and sexual transmission (topic

177 Rabies can be prevented with prompt postexposure prophylaxis, but this is costly and often i

178 ction, indications for vaccination, therapy, postexposure prophylaxis, decontamination of the environ

179 anagement of exposures including the role of postexposure prophylaxis.

180 rter incubation periods if they had received postexposure prophylaxis.

181 arts of Canada testing hydroxychloroquine as postexposure prophylaxis.

182 sure to communicable diseases for receipt of postexposure prophylaxis.

183 let regimen for human immunodeficiency virus postexposure prophylaxis.

184 romised children to varicella often requires postexposure prophylaxis.

185 e has similar efficacy to immune globulin as postexposure prophylaxis.

186 es prevention after an animal bite is prompt postexposure prophylaxis.

187 the incidence of rabies is low, many receive postexposure prophylaxis.

188 m that this regimen could be appropriate for postexposure prophylaxis.

189 rs for preventing HIV-1 transmission and for postexposure prophylaxis.

190 ctive antimicrobial agents for treatment and postexposure prophylaxis.

191 present to health care workers too late for postexposure prophylaxis.

192 HIV exposure, similar to recommendations for postexposure prophylaxis.

193 ents experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus dis

194 ed needles, or recent use of nonoccupational postexposure prophylaxis; ongoing use of preexposure pro

195 This is the first demonstration of complete postexposure protection against an Ebola virus in nonhum

196 Postexposure protection against MARV in non-human primat

197 mselves for endosomal delivery and conferred postexposure protection against multiple ebolaviruses in

198 This complete postexposure protection against ZEBOV in non-human prima

199 us platform has been successful in providing postexposure protection in nonhuman primates.

200 Postexposure protection was only observed in vaccinated

201 and potentially identify novel correlates of postexposure protection, we performed a similar experime

202 promising strategy to develop a single-dose postexposure rabies vaccine where the generation of earl

203 Postexposure recovery of threshold sensitivity has been

204 out the course of infection from 1 to 9 days postexposure, representing the full course of the infect

205 d AGP [0.9 (0.8-1.2) g/L] on day 3 and day 4 postexposure, respectively.

206 uals, protection against smallpox during the postexposure revaccination period may require T cell mem

207 without prespecifying the specific events or postexposure risk intervals of concern.

208 the potential of replacing current pre- and postexposure RV vaccines.

209 d of 92 serum samples (10 preexposure and 82 postexposure serum samples) from 10 adult beagles experi

210 In the postexposure setting, intravenous administration of ETI-

211 is study we show, both in a preventative and postexposure setting, that humanized mice infected with

212 important for the protection against RABV in postexposure settings.

213 on against rabies virus (RABV) infections in postexposure settings.

214 h the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no evidence of clinical illness and su

215 in leaf leachates were also highest for the postexposure silver birch leaves; scanning electron micr

216 We estimated the effectiveness of postexposure smallpox vaccination in preventing or modif

217 ics were critically reviewed and 3 different postexposure strategies were identified as being farthes

218 In therapeutic postexposure studies, human gamma globulin partially pro

219 RIID F6-H2 is an effective postexposure SUDV therapy and provides a potential treat

220 These changes persisted for 24 h postexposure, suggesting heritable modifications.

221 ys postexposure; late infection, 7 to 9 days postexposure) that was led by a robust innate immune res

222 However, after colonization (40 or more days postexposure), the opposite was true and RAMS culture wa

223 fected mice was measured by q-PCR at 8 weeks postexposure; the numbers of spirochetes in these tissue

224 in, blocks viral fusion, and shows promising postexposure therapeutic activity.

225 to consider T-cell targeting as a potential postexposure therapeutic strategy against severe Lassa f

226 In postexposure therapeutic trials in mice, a single dose o

227 potential to be developed as a life-saving, postexposure therapy against anthrax.

228 n mAbs, for achieving a safe and efficacious postexposure therapy for anthrax.

229 s have highlighted the need for an efficient postexposure therapy for Bacillus anthracis infection.

230 IFN-beta may have promise as an adjunctive postexposure therapy in filovirus infection.

231 Moreover, a 9-day postexposure therapy that was initiated 3 days after vir

232 Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019

233 Five MAbs functioned efficiently as postexposure therapy when administered as a single dose,

234 Postexposure therapy with hydroxychloroquine did not pre

235 d 16NS1 also demonstrated marked efficacy as postexposure therapy, even when administered as a single

236 lonal antibodies (MAbs) that can function as postexposure therapy, we generated a panel of 82 new MAb

237 e goal of identifying MAbs that can serve as postexposure therapy, we investigated in detail the func

238 yield after exposure varied as a function of postexposure time.

239 eks) showed essentially no shift at the same postexposure time.

240 rtality, particularly over a chronic (months postexposure) time scale, though not beyond naturally oc

241 nd held with unexposed cohorts for different postexposure times (2-96 weeks).

242 However, when held for long postexposure times, animals with previous exposure demon

243 The disease risk in the 30 days postexposure to an index-case patient was highest among

244 Quail were euthanized between 1 and 24 h postexposure to assess toxicokinetics.

245 idual MAbs protected mice well both pre- and postexposure to BoNT/A holotoxin.

246 ABA test showed that all the seeded cells postexposure to flow were viable, and significantly high

247 e group of mice was dosed and sacrificed 3 h postexposure to investigate tissue metabolite levels.

248 ion of this receptor that is seen in T cells postexposure to TGF-beta.

249 ercent recovery of activity at 7 min and 4 h postexposure to the inhibitor, were also determined.

250 Postexposure treatment (PET) of wild-type rabies virus (

251 ve also shown utility when administered as a postexposure treatment against filovirus infections, and

252 Successful postexposure treatment for inhalation anthrax is thought

253 nant vesicular stomatitis virus (rVSV), as a postexposure treatment for MARV haemorrhagic fever.

254 ility of inhaled antibodies as a fast-acting postexposure treatment for plague.

255 Vaccine and postexposure treatment have been effective in preventing

256 nical symptoms of rabies appear conventional postexposure treatment is unsuccessful.

257 ocess, but will also help to establish novel postexposure treatment modalities.

258 s become an important therapeutic target for postexposure treatment of botulism.

259 ccines, but also could be equally useful for postexposure treatment of filoviral infections.

260 y, we analyzed the potential of VSV-EBOV for postexposure treatment of rhesus macaques infected with

261 otential of RNA interference as an effective postexposure treatment strategy for people infected with

262 were treated with the rVSV MARV vectors as a postexposure treatment survived a high-dose lethal chall

263 Time to immunity and postexposure treatment were evaluated by immunizing hams

264 Here we show that early postexposure treatment with IFN-beta significantly incre

265 Postexposure treatment with MAb 201 can alleviate the vi

266 ne but demonstrates only limited efficacy in postexposure treatment.

267 rus (rVSV)-based vaccines make them suitable postexposure treatments against the filoviruses Ebola vi

268 Current postexposure treatments are inadequate at later stages o

269 al experimental conditions and suggests that postexposure treatments may need to be NiV strain specif

270 Two (66%) of three rhesus monkeys given four postexposure treatments of the pooled anti-ZEBOV siRNAs

271 infection, whereas all macaques given seven postexposure treatments were protected.

272 man exposure highlight the need for pre- and postexposure treatments.

273 mpleted screening, 27% had an initial but no postexposure tuberculin skin test, 12% were not screened

274 A new postexposure tuberculosis vaccine offers greatest potent

275 re significantly elevated (p < 0.05) in 24 h postexposure urine despite large between-subject variati

276 been demonstrated to inhibit anthrax toxin, postexposure use of DNI-based vaccines, including conjug

277 lyzed genome-wide transcriptional activities postexposure using an Affymetrix GeneChip microarray.

278 sera of individual PND 3 pups collected 1 hr postexposure utilizing ultra-high-pressure tandem mass s

279 protection by the VRP vaccine, and show that postexposure vaccination can confer protection from leth

280 These data provide evidence that postexposure vaccination can shorten the duration of ant

281 High postexposure vaccination effectiveness for preventing or

282 Thus postexposure vaccination enhanced the protection afforde

283 if VSVDeltaG-ZEBOV is safe or effective for postexposure vaccination in humans who have experienced

284 This result suggests that protection from postexposure vaccination may be antigen unspecific and d

285 primates and provides further evidence that postexposure vaccination may have utility in treating ex

286 Therefore, postexposure vaccination of adults with mycobacterial an

287 ently, rabies control in Tamil Nadu involves postexposure vaccination of humans after dog bites, wher

288 provides an accessible model for evaluating postexposure vaccination protocols that might be used in

289 Postexposure vaccination strategies rely on a rapid indu

290 t was offered, and provided his consent for, postexposure vaccination with an experimental vaccine av

291 ve immunotherapy with monoclonal antibodies, postexposure vaccination with constructs involving viral

292 In this patient, postexposure vaccination with VSVDeltaG-ZEBOV induced a

293 acy testing of smallpox vaccines in pre- and postexposure vaccine testing, which is important for pub

294 t rabies viruses (RABV) are promising rabies postexposure vaccines due to their prompt and potent sti

295 either method in the initial days (1 and 3) postexposure, we observed PrP(CWD) seeding activity and

296 nd RST3 isolates, except during the 2nd week postexposure, when the RST1 isolates displayed a markedl

297 olymorphonuclear leukocytes as early as 1 hr postexposure, which is indicative of mobilization of the

298 of gamma-H2AX foci was observed at 6 to 12 h postexposure, which was followed by activation of apopto

299 ARV)-infected NHPs were treated 15 to 30 min postexposure with virus-specific IgG, with additional tr

300 ed hyaluronan synthase Has1 mRNA already 4 h postexposure, with a return to control level by 24 h.